Supplementary Figure 1.docx (137.63 kB)

Supplementary Figure 1. Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis.

figure

posted on 2021-06-30, 08:45 authored by David L Kaplan, Brian L Ung, Corey Pelletier, Chuka Udeze, Ibrahim Khilfeh, Marc Tian

Supplementary Figure 1. Mean PPPM healthcare costs pre- and post-switch among patients who switched

Funding

This study was funded by Celgene

History

Usage metrics

Read the peer-reviewed publication

Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis.

Journal of Comparative Effectiveness Research

Categories

Rheumatology and arthritis

Keywords

apremilast healthcare costs IL inhibitors psoriatic arthritis TNF inhibitors treatment adherence treatment patterns Rheumatology and Arthritis

Licence

CC BY-NC-ND 4.0

Exports